On Technology
Marc Belsky: Radiopharmaceuticals represent an exciting frontier in cancer treatment. Our approach combines targeted delivery with radiation therapy to attack tumors while sparing healthy tissue. We deliver radiation directly to cancer cells using specialized carriers.
This targeted approach can potentially improve both efficacy – by getting more radiation to the tumor – and tolerability – by reducing exposure to normal tissues.
On Clinical Development
Q: Where are your programs in development?
Marc Belsky: Our lead program is advancing through clinical trials with encouraging preliminary results. We are seeing responses in patients who have failed multiple prior therapies, which is particularly meaningful in aggressive cancers.
We are also developing our pipeline with additional indications and isotope combinations that could expand our addressable market.
On Manufacturing
Q: How are you addressing manufacturing challenges?
Marc Belsky: Radiopharmaceutical manufacturing is complex due to the short half-life of radioactive isotopes. We have invested significantly in manufacturing capabilities and supply chain partnerships to support clinical and commercial scale production.
Our manufacturing strategy includes both internal capabilities and external partnerships to ensure reliable supply.
On Market Opportunity
Q: How big is the radiopharmaceutical opportunity?
Marc Belsky: The radiopharmaceutical market is growing rapidly, driven by clinical successes and strategic activity like Novartis’s acquisition of AAA. We believe we are still in the early innings of radiopharmaceutical adoption in oncology.